Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3339 - Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes

Date

11 Sep 2017

Session

Poster display session

Presenters

Adam Jassowicz

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

A. Jassowicz1, L. Liu2, H. Huang1, D.S. Hong1, A. Naing1, V. Subbiah1, S.A. Piha-Paul1, J. Toung2, R. Vijayaraghavan2, R. Zhang2, H. Kang2, S. Fu1, A.M. Tsimberiodou1, C. Lu3, C. Eng4, S. Moulder5, S. Kopetz6, R. Amaria7, F. Meric-Bernstam1, F. Janku1

Author affiliations

  • 1 Department Of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Oncology, Illumina, Inc., San Francisco/US
  • 3 Department Of Thoracic/head And Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Department Of Gastrointestinal (gi) Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 5 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 6 Gi Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 7 Department Of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
More

Resources

Abstract 3339

Background

Plasma cell-free DNA (cfDNA) sampling from patients with advanced cancers offers a minimally invasive source of tumor DNA for molecular testing, including methylation profiling. Tumor sequencing at disease progression offers insights into cancer biology, but is often not done because of logistical and other challenges associated with tumor biopsies.

Methods

Plasma samples were collected from patients with advanced breast, colorectal, non-small cell lung cancer (NSCLC) and melanoma at the time of disease progression and/or on therapy. Up to 30 ng (median 18ng) of plasma cfDNA was tested with the pan-cancer methylation panel to target a total of 10,888 CpG sites using an Illumina HiSeq2500 sequencer to calculate methylation scores. Methylation scores were correlated with cancer types and clinical outcomes.

Results

Of 69 plasma cfDNA samples collected from patients (colorectal cancer, 28; NSCLC, 18, breast cancer, 12; melanoma, 11) at disease progression, methylation scores were consistent with the presence of cancer in 84% (58/69); while in 79% (46/58) of plasma cfDNA samples, methylation scores accurately classified the underlying cancer type. High methylation scores in plasma cfDNA samples collected at disease progression compared to low methylation scores were associated with shorter survival irrespective of the tumor type (3.9 vs 10.4 months, P 

Conclusions

Methylation scores from plasma cfDNA collected at disease progression from patients with advanced cancers accurately classify underlying cancer types and are associated with survival, TTF and RECIST responses.

Clinical trial identification

MD Anderson Protocols laboratory protocols LAB10-0334 and PA13-0956

Legal entity responsible for the study

MD Anderson Cancer Center

Funding

Sidney Kimmel Foundation for Cancer Research (Filip Janku); Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy (Filip Janku); National Center for Advancing Translational Sciences (grant no. UL1 TR000371); National Institutes of Health through MD Anderson’s Cancer Center Support Grant (P30 CA016672); Illumina.

Disclosure

L. Liu, J. Toung, R. Vijayaraghavan, R. Zhang, H. Kang: Employee and stock ownership Illumina, Inc. F. Janku: Scientific Advisory Boards: Illumina, Guardant Health; Paid consulting: Trovagene; Stocks: Trovagene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.